Pentixapharm Holding AG (FRA:PTP)

Market Cap	36.33M
Revenue (ttm)	1.52M
Net Income (ttm)	-26.50M
Shares Out	n/a
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,483
Average Volume	120
Open	1.578
Previous Close	1.516
Day's Range	1.440 - 1.578
52-Week Range	1.312 - 4.650
Beta	n/a
RSI	42.87
Earnings Date	Nov 12, 2025

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2019
• Employees: 75
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PTP

Financial Performance

In 2024, Pentixapharm Holding AG's revenue was 1.40 million, a decrease of -78.47% compared to the previous year's 6.51 million. Losses were -13.98 million, 82.9% more than in 2023.